Document is current

Any future updates will be listed below

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial

Crossref DOI link: https://doi.org/10.1038/s41523-022-00462-6

Published Online: 2022-09-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark